Notably, our findings also suggest that PARPi may also demonstrate a therapeutic window in Fanconi Anemia patients with biallelic FANCA mutations who develop cancer—often associated with Myc amplification and replication stress-associated genomic instability72,73—providing a targeted therapy for a rare but challenging clinical scenario. Here, MYC is linked to Fanconi anemia.